Shares of Tempus AI jumped 6.2% to $51.84 on Tuesday, snapping back from a volatile week after a Seeking Alpha analyst upgraded the stock to Buy from Hold, arguing the recent selloff created a better entry point. The move raises a pointed question: is this a genuine bargain, or are investors chasing a growth story that still burns cash at an alarming rate?
A Rough Week Made the Stock Look Cheaper — but the Losses Haven't Shrunk. TEM's share price fell 13% over the prior week , and the upgrade hinges on that pullback resetting the valuation. Yet the fundamentals haven't improved in a week. The company posted a GAAP net loss of $125.9 million in Q1 2026, nearly double the $68 million loss a year earlier . The consensus expected loss for 2026 has also widened, from -$1.67 to -$2.04 per share . A cheaper stock is not the same as a profitable one.
Revenue Is Growing Fast, and the Data Business Is the Story to Watch. Q1 revenue hit $348.1 million, up 36%, with gross profit rising 43% to $222 million and gross margin expanding to 63.8% — a sign the higher-margin data licensing business is gaining share in the mix. Data and applications revenue grew 40.5% year-over-year, with data licensing specifically up 44.1% . That segment, where Tempus sells access to its massive library of anonymized patient records to pharma companies, carries fatter margins than lab testing and is what separates Tempus from a traditional diagnostics company.
Wall Street's Average Target Still Sits Far Above the Current Price. The consensus price target across 15 analysts is $67.20 , implying roughly 30% upside from today's price. But there's a wide spread: Jefferies has a target as low as $35, while Morgan Stanley sits at $70 . That divergence reflects genuine uncertainty about whether Tempus can convert growth into positive cash flow.
An FDA Win and Big Pharma Deals Provide Near-Term Catalysts — and Cover. The FDA recently approved Tempus's flagship cancer-sequencing test for a key tumor-only use, effectively upgrading the company from "interesting AI data play" to a regulated diagnostics platform . Meanwhile, an expanded Bristol Myers Squibb collaboration embeds Tempus's data into five oncology and neuroscience programs , creating the kind of sticky, multi-year revenue investors crave. Management has guided for ~$1.59 billion in 2026 revenue (~25% growth) and roughly $65 million in adjusted EBITDA — its first full year of operating-level profitability by that measure.
The upgrade gave the stock a jolt, but the real test is whether Tempus can narrow GAAP losses fast enough to reward shareholders before the cash cushion — currently $643.8 million — runs thin.